Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study

[1]  D. Lye,et al.  Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine Against Omicron Variant Among Elderly People in Singapore , 2022, Annals of Internal Medicine.

[2]  D. Barouch.  Covid-19 Vaccines — Immunity, Variants, Boosters , 2022, The New England journal of medicine.

[3]  G. Kochs,et al.  COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation , 2022, Nature Communications.

[4]  Ee Vien Low,et al.  Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months , 2022, JAMA network open.

[5]  M. Andrew,et al.  COVID-19 mRNA vaccine effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 delta (B.1.617.2) variant surge in the USA: a retrospective cohort study , 2022, The Lancet Healthy Longevity.

[6]  A. Sette,et al.  Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines , 2022, Science.

[7]  N. Pearce,et al.  Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil , 2022, Nature Communications.

[8]  Sarah E. Wilson,et al.  Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study , 2022, BMJ.

[9]  D. Follmann,et al.  Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial , 2022, Annals of Internal Medicine.

[10]  Qian Wang,et al.  Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5 , 2022, Nature.

[11]  E. Lau,et al.  Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study , 2022, The Lancet Infectious Diseases.

[12]  K. To,et al.  Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong , 2022, Nature Communications.

[13]  Fei Shao,et al.  BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.

[14]  P. Klenerman,et al.  Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum , 2022, Cell.

[15]  J. Haughney,et al.  Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial , 2022, The Lancet Infectious Diseases.

[16]  M. Davenport,et al.  Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast? , 2022, Nature Reviews Immunology.

[17]  R. Arbel,et al.  Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years , 2022, Nature Medicine.

[18]  O. Tsang,et al.  Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines , 2022, eBioMedicine.

[19]  E. Undurraga,et al.  Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study , 2022, The Lancet Global Health.

[20]  K. To,et al.  Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2 , 2022, The Lancet Microbe.

[21]  Henrik Nielsen,et al.  Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study , 2022, Clinical Microbiology and Infection.

[22]  V. Prendki,et al.  Caring for older adults during the COVID-19 pandemic , 2022, Clinical Microbiology and Infection.

[23]  Reed J. D. Sorensen,et al.  Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21 , 2022, The Lancet.

[24]  K. To,et al.  Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine , 2022, Emerging microbes & infections.

[25]  S. Vermund,et al.  Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination , 2022, Nature Medicine.

[26]  K. To,et al.  Immune Imprinting with Ancestral SARS-CoV-2 Strain Induced Potent Neutralizing Activity Against Omicron Sublineages BA.2, BA.2.12.1 and BA.4/5 , 2022, SSRN Electronic Journal.

[27]  OUP accepted manuscript , 2022, Clinical Infectious Diseases.

[28]  O. Tsang,et al.  Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients , 2021, medRxiv.

[29]  O. A. Ogun,et al.  Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study , 2021, The Lancet.

[30]  A. Walls,et al.  Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants , 2021, bioRxiv.

[31]  D. Stuart,et al.  Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom , 2021, Nature Microbiology.

[32]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[33]  D. Lauffenburger,et al.  Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[34]  Sandeep R. Pagali.  Caring for Older Adults During Covid-19 Pandemic , 2020 .

[35]  O. Tsang,et al.  High neutralizing antibody titer in intensive care unit patients with COVID-19 , 2020, Emerging microbes & infections.